JP6452258B2 - ペディオコッカス（Ｐｅｄｉｏｃｏｃｃｕｓ）とラクトバチルス（Ｌａｃｔｏｂａｃｉｌｌｕｓ）とを含む細菌の混合物を含む組成物、ならびにアルコールの影響を軽減するための方法 - Google Patents

ペディオコッカス（Ｐｅｄｉｏｃｏｃｃｕｓ）とラクトバチルス（Ｌａｃｔｏｂａｃｉｌｌｕｓ）とを含む細菌の混合物を含む組成物、ならびにアルコールの影響を軽減するための方法 Download PDF

Info

Publication number
JP6452258B2
JP6452258B2 JP2016513140A JP2016513140A JP6452258B2 JP 6452258 B2 JP6452258 B2 JP 6452258B2 JP 2016513140 A JP2016513140 A JP 2016513140A JP 2016513140 A JP2016513140 A JP 2016513140A JP 6452258 B2 JP6452258 B2 JP 6452258B2
Authority
JP
Japan
Prior art keywords
composition
mixture
tablet
powder
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016513140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521287A5 (cg-RX-API-DMAC7.html
JP2016521287A6 (ja
JP2016521287A (ja
Inventor
リチャード カーペンター
リチャード カーペンター
アミト カプール
アミト カプール
イー． ウェスリー ハフ
イー． ウェスリー ハフ
ナーラーヤン サレシュ
ナーラーヤン サレシュ
Original Assignee
バイオウィッシュ テクノロジーズ インコーポレイテッド
バイオウィッシュ テクノロジーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオウィッシュ テクノロジーズ インコーポレイテッド, バイオウィッシュ テクノロジーズ インコーポレイテッド filed Critical バイオウィッシュ テクノロジーズ インコーポレイテッド
Publication of JP2016521287A publication Critical patent/JP2016521287A/ja
Publication of JP2016521287A6 publication Critical patent/JP2016521287A6/ja
Publication of JP2016521287A5 publication Critical patent/JP2016521287A5/ja
Application granted granted Critical
Publication of JP6452258B2 publication Critical patent/JP6452258B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Jellies, Jams, And Syrups (AREA)
JP2016513140A 2013-05-10 2014-05-12 ペディオコッカス（Ｐｅｄｉｏｃｏｃｃｕｓ）とラクトバチルス（Ｌａｃｔｏｂａｃｉｌｌｕｓ）とを含む細菌の混合物を含む組成物、ならびにアルコールの影響を軽減するための方法 Expired - Fee Related JP6452258B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361821974P 2013-05-10 2013-05-10
US61/821,974 2013-05-10
PCT/US2014/037704 WO2014183117A1 (en) 2013-05-10 2014-05-12 Compositions comprising a mixture of bacteria comprising pedoiococcus and lactobacillus an methods for decreasing the effects of alcohols

Publications (4)

Publication Number Publication Date
JP2016521287A JP2016521287A (ja) 2016-07-21
JP2016521287A6 JP2016521287A6 (ja) 2016-10-06
JP2016521287A5 JP2016521287A5 (cg-RX-API-DMAC7.html) 2017-06-15
JP6452258B2 true JP6452258B2 (ja) 2019-01-16

Family

ID=50980375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016513140A Expired - Fee Related JP6452258B2 (ja) 2013-05-10 2014-05-12 ペディオコッカス（Ｐｅｄｉｏｃｏｃｃｕｓ）とラクトバチルス（Ｌａｃｔｏｂａｃｉｌｌｕｓ）とを含む細菌の混合物を含む組成物、ならびにアルコールの影響を軽減するための方法

Country Status (10)

Country Link
US (1) US10130664B2 (cg-RX-API-DMAC7.html)
EP (1) EP2994149A1 (cg-RX-API-DMAC7.html)
JP (1) JP6452258B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160013069A (cg-RX-API-DMAC7.html)
CN (1) CN106456679A (cg-RX-API-DMAC7.html)
AU (2) AU2014262427B2 (cg-RX-API-DMAC7.html)
CA (1) CA2911947A1 (cg-RX-API-DMAC7.html)
HK (1) HK1222584A1 (cg-RX-API-DMAC7.html)
RU (1) RU2671221C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014183117A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170005093A (ko) 2014-05-12 2017-01-11 바이오위시 테크놀로지스, 인크. 인간 건강 및 영양 향상을 위한 조성물 및 방법
KR101853603B1 (ko) * 2017-05-18 2018-05-02 주식회사 쎌바이오텍 알코올 또는 아세트알데하이드 분해용 프로바이오틱스를 포함하는 조성물
WO2019232026A1 (en) 2018-05-29 2019-12-05 BiOWiSH Technologies, Inc. Compositions and methods for improving survivability of aquatic animals
CN109350629B (zh) * 2018-08-09 2021-06-01 新乡医学院 一种用于治疗酒精戒断综合征的益生菌复合制剂及其制备方法
CN115919907A (zh) * 2021-08-31 2023-04-07 E·施约林 一种用于治疗和/或预防食物和/或酒精中毒的组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007867A2 (en) * 1996-08-22 1998-02-26 Bioteknologisk Institut Metabolically engineered lactic acid bacteria and means for providing same
US6953574B2 (en) * 2002-06-21 2005-10-11 Technology Commercialization, Inc. Method for producing a fermented hydrolyzed medium containing microorganisms
CN1993052B (zh) * 2004-07-29 2011-08-17 京都府 植物病害防除剂和防除方法
FR2881751B1 (fr) * 2005-02-07 2007-04-27 Virbac Sa Sa Compositions comprenant des micro-organismes deshydrates, leurs procedes de preparation, et leurs utilisations
KR100661032B1 (ko) * 2005-04-19 2006-12-22 주식회사한국야쿠르트 간 기능 개선, 혈중 알코올 감소 및 항산화에 유효한조성물
US20060263385A1 (en) 2005-05-17 2006-11-23 Fran Gare Composition to relieve side effects of alcohol intoxication
JP5413819B2 (ja) * 2008-02-08 2014-02-12 国立大学法人広島大学 肝機能改善剤およびその製造用ツール、ならびにこれらの利用
IT1392101B1 (it) 2008-12-12 2012-02-09 Zuccari Societa A Responsabilita Limitata In Breve Zuccari S R L Composizione comprendente isoflavoni
US9579353B2 (en) * 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
US9161957B2 (en) 2012-08-03 2015-10-20 Life Well Lived, Llc Compositions and methods for reducing blood alcohol content
CN104755092A (zh) * 2012-10-30 2015-07-01 雀巢产品技术援助有限公司 用于递送协同免疫作用的包含微粒和益生菌的组合物
CN102934809B (zh) * 2012-12-10 2014-04-30 济南大学 益生菌发酵中药制剂制备的组合物及其制备方法和应用

Also Published As

Publication number Publication date
US10130664B2 (en) 2018-11-20
CN106456679A (zh) 2017-02-22
EP2994149A1 (en) 2016-03-16
AU2014262427B2 (en) 2018-12-13
CA2911947A1 (en) 2014-11-13
AU2014262427A1 (en) 2015-11-26
AU2019201637A1 (en) 2019-04-11
RU2015152826A (ru) 2017-06-20
RU2671221C2 (ru) 2018-10-30
JP2016521287A (ja) 2016-07-21
KR20160013069A (ko) 2016-02-03
HK1222584A1 (zh) 2017-07-07
US20140335187A1 (en) 2014-11-13
WO2014183117A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
JP4594894B2 (ja) 肝機能の改善、血中アルコールの減少及び抗酸化に有効な組成物
EP2124972B1 (de) Verwendung einer zusammensetzung aus mineralstoffen und gegebenenfalls acetogenen und/oder butyrogenen bakterien zur vermeidung oder reduzierung von gasbildung im dickdarm eines säugetiers und dadurch bedingter abdominaler beschwerden
JP2009269925A (ja) Ｓｉｄｓに関連する細菌感染を処置するための共生乳酸細菌
AU2019201637A1 (en) Compositions Comprising a Mixture of Bacteria Comprising Pediococcus and Lactobacillus and Methods for Decreasing the Effects of Alcohols
JP2013504321A (ja) アレルギーの予防及び治療のためのプロバイオティクスから得られる非生存型物質
US11045509B2 (en) Tributyrin compositions and methods therefor
AU2011314299B2 (en) Compositions and methods for augmenting kidney function
JP2016521287A6 (ja) ペディオコッカス（Ｐｅｄｉｏｃｏｃｃｕｓ）とラクトバチルス（Ｌａｃｔｏｂａｃｉｌｌｕｓ）とを含む細菌の混合物を含む組成物、ならびにアルコールの影響を軽減するための方法
JP2002522393A (ja) 共生乳酸産生細菌を使用する、栄養材料の溶解度を増大するための方法
JP5592640B2 (ja) 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤、その製造方法、視床下部−下垂体−副腎皮質系の活動抑制剤、及び交感神経−副腎髄質系の活動抑制剤
TWI642363B (zh) Ｑｏｌ改善或維持劑
JPWO2005099725A1 (ja) 炎症性腸疾患予防および／または治療剤
JP2005013211A (ja) 乳酸菌含有食品組成物
CN108403970B (zh) 一种益生元组合物及其制备方法和应用
JP2007126399A (ja) グルタチオン増加用組成物
KR102923434B1 (ko) 숙취 해소용 프로바이오틱스 제제 및 이의 제조방법
Code Proprietary human strain probiotic for extra daily support
JP2026008765A (ja) シンバイオティクスの、グルカゴン様ペプチド－１を上昇させる組成物の調製における用途
WO2024104828A1 (en) Compositions
TW202602432A (zh) 合生元用於製備提升類升糖素胜肽-1的組合物的用途
SUBHASHREE DEVELOPMENT OF PLANT BASED PROBIOTIC NUTRITIONAL SUPPLEMENT TO ENHANCE GUT PROBIOTIC MICROFLORA
HK1172928A (en) Probiotic derived non-viable material for allergy prevention and treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181210

R150 Certificate of patent or registration of utility model

Ref document number: 6452258

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees